Cognition Therapeutics is preparing to announce its Q1 earnings report on March 23rd. The company’s stock experienced a decline of 4.5% on Tuesday, opening at $1.70. Which is lower than its 1-year high of $6.27. Institutional investors have been buying and selling CGTX shares, with Vanguard Group Inc. increasing its position in the company by 465.7% in Q3. Cognition Therapeutics (NSD:CGTX) is a clinical-stage biopharmaceutical company that is focused on developing drugs to treat neurodegenerative diseases such as Alzheimer’s. The company is currently conducting Phase 2 clinical trials on Elayta, its lead product candidate. Which targets toxic oligomers that are believed to contribute to the development of Alzheimer’s disease. Despite the recent dip in the company’s stock price. CGTX remains hopeful that its ongoing clinical trials will lead to positive results and the advancement of Alzheimer’s disease treatments.
Cognition Therapeutics Stock Analysis
Cognition Inc. is expected to have an average analyst target price of USD 10.50 over the next 12 months based on forecasts from 2 analysts. The company’s average analyst rating is Strong Buy. However, Stock Target Advisor’s own analysis of Cognition Therapeutics Inc. is Bearish, with 1 positive and 7 negative signals. The company’s last closing stock price was USD 1.70, having increased by +4.29% over the past week, but decreased by -5.56% over the past month and -43.14% over the last year.
Company Overview
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage that focuses on the research and development of small molecule therapeutics. Their aim is to develop treatments for age-related degenerative diseases and disorders of the central nervous system and retina. The company’s lead product candidate, CT1812, is a sigma-2 receptor antagonist that is currently undergoing Phase II clinical trials for mild-to-moderate Alzheimer’s disease and dementia with Lewy bodies (DLB). CT1812 has completed a Phase I clinical trial for early-stage Alzheimer’s disease. The company is also developing CT2168, a treatment for synucleinopathies such as DLB and Parkinson’s disease, and CT2074 to treat dry age-related macular degeneration (AMD). Cognition Therapeutics, Inc. was established in 2007 and is headquartered in Purchase, New York.
